Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma.
Hepatocellular carcinoma (HCC) is one of the most lethal and prevalent cancers in humans. The molecular mechanisms leading to the development of HCC are extremely complicated and consist of prominent genetic, genomic, and epigenetic alterations. This review summarizes the current knowledge of the role of epigenetic aberrations, including changes in DNA methylation, histone modifications, and expression of microRNAs in the pathogenesis of HCC. It also emphasizes that identification of the underlying epigenetic alterations that drive cell transformation and promote development and progression of HCC is crucially important for understanding mechanisms of hepatocarcinogenesis, its detection, therapeutic intervention, and prevention.
Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, AR 72079, United States. Electronic address: igor.pogribny@fda.hhs.gov.
Igor P
IP
Pogribny
Ivan
I
Rusyn
D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D019175:DNA Methylation; D018450:Disease Progression; D044127:Epigenesis, Genetic; D015972:Gene Expression Regulation, Neoplastic; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D006657:Histones / Q000378:metabolism; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D008114:Liver Neoplasms, Experimental / Q000235:genetics; D035683:MicroRNAs / Q000235:genetics; D010641:Phenotype; D011237:Predictive Value of Tests; D011379:Prognosis
D014408:Biomarkers, Tumor; D006657:Histones; D035683:MicroRNAs